Remix Therapeutics is developing small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Location: United States, Massachusetts, Cambridge
Total raised: $211M
Investors 3
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 26.03.2022 | ARCH Ventu... | archventur... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.01.2024 | - | $60M | - |
| 18.05.2022 | Series B | $70M | Foresite C... |
| 08.12.2020 | Series A | $81M | - |
Mentions in press and media 16
| Date | Title | Description |
| 28.05.2024 | Remix Therapeutics Announces Participation in Jefferies Healthcare Conference | WATERTOWN, Mass., May 28, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced ... |
| 03.01.2024 | Remix Therapeutics Closes $60M Financing | Remix Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing small molecule therapies, raised $60M in funding. The round was led by The Column Group with participation from existing investors Atlas Venture, Fore... |
| 09.01.2023 | Healthcare Hires of Note | ProofPilot, a digital protocol automation platform for clinical trials, has added Bernadette Tosti to its executive leadership team in the role of chief product officer this week. Tosti has more than 15 years of experience in the digital cl... |
| 18.05.2022 | Remix Therapeutics reels in $70M Series B | Remix Therapeutics has raised $70 million from investors including Surveyor, Foresite Capital and Arch Venture Partners. Based in the Boston area, the company is developing small-molecule therapies that work to treat cancer and other diseas... |
| 18.05.2022 | Remix Therapeutics Raises $70 Million in Series B Financing | Remix Therapeutics, a Cambridge, MA-based biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, raised $70M in Series B funding. The round was led by Su... |
| 17.05.2022 | Remix closes $70M funding with pipeline 'really humming,' but to what tune? | RNA-focused Remix Therapeutics has wrapped up a $70 million series B, bringing its total fundraising haul north of $150 million even as precise pipeline details remain unknown. The closed round, announced Tuesday, is the second lap around t... |
| 17.02.2022 | J&J partners with startup Remix, aiming to treat disease by “tuning” RNA | Much drug research has focused on small molecules that target disease-causing proteins. However, the easy protein targets have already been drugged so some biotech companies are going upstream by addressing RNA, the molecules that carry the... |
| 09.12.2020 | Remix Therapeutics launches with $81M Series A | Remix Therapeutics has raised $81 million in a round led by Foresite Capital, with participation from Atlas Ventures and The Column Group. The Cambridge, Mass.-based biotech startup is developing small-molecule therapies that work to treat ... |
| 08.12.2020 | Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing | |
| 08.12.2020 | The Briefing: Calm Hits $2B Valuation With New Round, Dragos Lands $110M, And More | 8 Shares Email Facebook Twitter LinkedIn Here’s what you need to know today in startup and venture news, updated by the Crunchbase News staff throughout the day to keep you in the know. Subscribe to the Crunchbase Daily Calm raises $75M at ... |
Show more